Table 3.
GBRS outcome mean scores in placebo and enzyme groups after treatment
| Outcome measure | Group 1 | Group 2 | Significance | ||
|---|---|---|---|---|---|
|
|
|
||||
| Before enzyme therapy | After enzyme therapy | Before placebo | After placebo | ||
| Child’s general behavior | 3.01±1.3 | 5.5±0.75 | 3.50±0.7 | 3.39±1.01 | p*=NS, p†<0.001 |
| Nighttime sleeping | 3.89±1.3 | 4.02±1.20 | 3.84±1.0 | 3.98±0.89 | p*,†=NS |
| Gastrointestinal symptoms‡ | 3.79±0.61 | 6.03±0.56 | 4.02±0.28 | 4.02±0.23 | p*=NS, p†<0.001 |
| Daytime wetting | 3.86±0.67 | 3.97±0.88 | 3.92±0.83 | 4.03±1.04 | p*,†=NS |
| Nighttime wetting | 4.60±0.97 | 4.23±1.25 | 3.92±0.6 | 4.09±0.64 | p*,†=NS |
Values are presented as mean±standard deviation.
GBRS, Global Behavior Rating Scales.
Group 1, group received digestive enzymes; group 2, placebo group.
p*, comparison between enzyme and placebo groups before treatment;
p†, comparison between enzyme and placebo groups after treatment;
NS, non-significant (p≤0.05: significant).
‡
Quality of stools, abdominal pain, vomiting, food variety.